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Drug survival analyses are frequently used to evaluate the per-
formance of drugs used in chronic conditions in real-world
practice, such as biologics for psoriasis.1 The hypothesis is that
a long drug survival indicates that the drug performs well. It
is assumed that, if there were problems such as ineffectiveness
or side-effects, the drug would have been stopped earlier.2
Ultimately, it would be valuable for physicians to know
beforehand which patients are likely to have successful or
unsuccessful drug survival, enhancing personalized medicine.
Predictive factors that guide physicians in decision making are
needed to fulfil this purpose.
In this issue of the BJD, Mourad et al. report a systematic
review and meta-analysis regarding predictive factors for drug
survival of biologics in psoriasis.3 An extensive search has
been carried out leading to the inclusion of 16 cohort studies
(n = 32 194) for the review. Three predictive factors were
further investigated in a meta-analysis: sex, obesity and a diag-
nosis of psoriatic arthritis. Female sex and obesity were associ-
ated with a higher chance of discontinuation on a subset of
biologics, while having a diagnosis of psoriatic arthritis led to
lower rates of discontinuation. In a stratified analysis, it was
shown that female sex and obesity led to more discontinua-
tions because of adverse events, and that obesity was also
associated with more discontinuations as a result of ineffec-
tiveness.
The study by Mourad et al. provides important insights into
which factors may pose a risk for discontinuation of specific
biologics. It could be relevant to choose a drug based on
prognostic factors that are present in a specific patient. This
may guide physicians already in choosing the right biologic
for the individual patient. It should be noted that a direct cau-
sal relationship between these prognostic factors and drug sur-
vival cannot be estimated from such observational studies.
This should be an important topic for future aetiological
research. For example, to improve drug survival in women,
who more often stop biologics as a result of safety issues, dif-
ferent questions should be answered first. Important questions
would be: do women have more safety issues when taking
biologics or do they only report more issues? Which safety
issues are present? Are preventive measures regarding safety
possible? With regards to obesity, other questions are relevant,
such as, is weight loss really leading to better survival rates
before or during treatment? Should we base our dosages more
on weight?
Studies like the present article by Mourad et al. are impor-
tant in an era where multiple treatment options are available,
as is the case in psoriasis care today. With many ongoing drug
developments, also for other chronic skin diseases, a careful
examination of predictive factors for treatment success will
remain relevant.
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In order to conduct meaningful clinical trials on interventions
for disease, the use of proper measurement instruments is key.
This is increasingly acknowledged and large initiatives are
being founded to improve the field of measurement in medi-
cine. One of these initiatives is called COnsensus-based Stan-
dards for the selection of health Measurement INstruments
(COSMIN),1 which mainly aims to develop core outcome sets
(COSs), containing an agreed minimum set of outcomes that
should be measured and reported in all clinical trials of a
specific disease.2 Such COSs are composed of high-quality
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